Brinker Capital Investments’s BridgeBio Pharma BBIO Stock Holding History

Brinker Capital Investments’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.79M	Buy	24,100 +5,186	+27%	+$363K	0.01%	858
2026 Q1	$1.4M	Buy	18,914 +13,280	+236%	+$963K	0.01%	929
2025 Q4	$431K	Buy	+5,634	New	+$370K	﹤0.01%	1650
2024 Q1	–	Sell	-6,192	Closed	-$240K	–	1686
2023 Q4	$240K	Buy	+6,192	New	+$186K	﹤0.01%	1499

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Brinker Capital Investments's BBIO Position: Q2 2026 in Review

Brinker Capital Investments increased its BridgeBio Pharma (BBIO) stake by 27% in Q2 2026, buying an estimated $363K and bringing the position to 24,100 shares worth $1.79M. The position accounts for 0.01% of the portfolio, ranked #858.

Brinker Capital Investments first reported a position in BBIO in Q4 2023 and has held it in 4 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Brinker Capital Investments held 24,100 shares of BridgeBio Pharma worth $1.79M as of Q2 2026.
Brinker Capital Investments bought 5,186 BridgeBio Pharma shares in Q2 2026, an estimated $363K.
BridgeBio Pharma made up 0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #858 holding.
Brinker Capital Investments first reported a position in BridgeBio Pharma in Q4 2023 and has held it in 4 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.